Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ESRRG | P62508 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30984901 | 0.90 | SIRT6 (0.63) | SIRT6ADRB1MAPTCRBNALDH1A1 | |
| SCHEMBL10035909 | 0.86 | SIRT6 (0.71) | SIRT6ADRB1MAPTCRBNALDH1A1 | |
| SCHEMBL30985176 | 0.85 | SIRT6 (0.50) | SIRT6ADRB1MAPTCRBNALDH1A1 | |
| SCHEMBL4290276 | 0.84 | ESRRG (0.63) | SIRT6ADRB1MAPTCRBNALDH1A1 | |
| SCHEMBL4290270 | 0.84 | ESRRG (0.63) | SIRT6ADRB1MAPTCRBNALDH1A1 | |
| SCHEMBL25447124 | 0.84 | SIRT6 (0.58) | SIRT6ADRB1MAPTCRBNALDH1A1 | |
| SCHEMBL30984980 | 0.84 | MEN1 (0.63) | SIRT6ADRB1MAPTCRBNALDH1A1 | |
| SCHEMBL13247587 | 0.81 | SIRT6 (0.73) | SIRT6ADRB1MAPTCRBNALDH1A1 | |
| SCHEMBL30985187 | 0.81 | CRBN (0.62) | SIRT6ADRB1MAPTCRBNALDH1A1 | |
| SCHEMBL18283605 | 0.81 | MAPT (0.58) | SIRT6ADRB1MAPTCRBNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113614087-B | WEE1 inhibitor and preparation and application thereof | 首药控股(北京)股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220324868-A1 | Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-10-13 | — | — | US | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-3564232-B1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2022-01-26 | — | — | EP | disclosed |
| US-10954216-B2 | BMP-signal-inhibiting compound | RIKEN (JP) | 2021-03-23 | — | — | US | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2019-11-07 | — | — | US | disclosed |
| EP-3564232-A1 | BMP-SIGNAL-INHIBITING COMPOUND | Riken (JP) | 2019-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954216-B2 | BMP-signal-inhibiting compound | BMP1, BMP2, BMP4 | SIRT6 2172/4885ADRB1 2265/4885MAPT 4782/4885 |
| US-20220324868-A1 | Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor | WEE1, WEE2, WASF2 | SIRT6 1389/4885ADRB1 4106/4885MAPT 4504/4885 |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | BMP1, BMP2, BMPR2 | SIRT6 1885/4885ADRB1 2143/4885MAPT 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.